Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1β
暂无分享,去创建一个
B. Sipos | G. Klöppel | H. Kalthoff | A. Arlt | T. Sebens | U. Fölsch | M. Kruse | H. Schäfer | S. Müerköster | K. Wegehenkel | M. Witt
[1] H. Kalthoff,et al. Usage of the NF‐κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer , 2003, International journal of cancer.
[2] M. Löhr,et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform , 2003, Virchows Archiv.
[3] A. Doseff,et al. Presentation of Nitric Oxide Regulates Monocyte Survival through Effects on Caspase-9 and Caspase-3 Activation* , 2003, The Journal of Biological Chemistry.
[4] J. Abbruzzese,et al. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis , 2003, Oncogene.
[5] V. Trajković,et al. The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells , 2003, Cellular and Molecular Life Sciences CMLS.
[6] P. Chan,et al. Aspirin Inhibits p44/42 Mitogen-Activated Protein Kinase and Is Protective Against Hypoxia/Reoxygenation Neuronal Damage , 2003, Stroke.
[7] N. Fusenig,et al. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. , 2002, Differentiation; research in biological diversity.
[8] Ding-I Yang,et al. NO‐Mediated Chemoresistance in C6 Glioma Cells , 2002, Annals of the New York Academy of Sciences.
[9] A. Arlt,et al. Autocrine Production of Interleukin 1β Confers Constitutive Nuclear Factor κB Activity and Chemoresistance in Pancreatic Carcinoma Cell Lines , 2002 .
[10] U. Fölsch,et al. Isolation, Long-term Culture, and Characterization of Rat Pancreatic Fibroblastoid/Stellate Cells , 2001, Pancreas.
[11] R H Hruban,et al. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. , 2001, Cancer research.
[12] H. Kalthoff,et al. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin , 2001, Oncogene.
[13] F. Sigaux,et al. Contribution of Nitric Oxide to the Apoptotic Process in Human B Cell Chronic Lymphocytic Leukaemia , 2001, Leukemia & lymphoma.
[14] Marty W. Mayo,et al. NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis , 1999, Molecular and Cellular Biology.
[15] Claus Scheidereit,et al. NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition , 1999, Molecular and Cellular Biology.
[16] J. Cusack,et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.
[17] C. Y. Wang,et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.
[18] Z. Ao,et al. IEX-1L, an Apoptosis Inhibitor Involved in NF-κB-Mediated Cell Survival , 1998 .
[19] F. Sigaux,et al. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. , 1998, Blood.
[20] James B. Mitchell,et al. The multifaceted roles of nitric oxide in cancer. , 1998, Carcinogenesis.
[21] I. Fidler,et al. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase , 1998, Cancer and Metastasis Reviews.
[22] B. Dörken,et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.
[23] A. E. Rogers,et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.
[24] I. Fidler,et al. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. , 1997, Journal of the National Cancer Institute.
[25] T. Billiar,et al. New insights into the regulation of inducible nitric oxide synthesis. , 1994, The American journal of physiology.
[26] C Caldas,et al. Allelotype of pancreatic adenocarcinoma. , 1994, Cancer research.
[27] S. Moncada,et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.
[28] Seaver,et al. Nitric oxide as a secretory product of mammalian cells , 2004 .
[29] R. Hruban,et al. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. , 2002, The American journal of pathology.
[30] J. K. Lee,et al. Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristics, and patient survival in pancreatic cancer , 2001, International journal of pancreatology : official journal of the International Association of Pancreatology.
[31] Douglas B. Evans,et al. The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .
[32] K. Lillemoe. Palliative therapy for pancreatic cancer. , 1998, Surgical oncology clinics of North America.
[33] S. Snyder,et al. Nitric oxide: a neural messenger. , 1995, Annual review of cell and developmental biology.